selected publications
-
Accelerated single cell seeding in relapsed multiple myeloma.
Nature communications.
2020
Academic Article
GET IT
Times cited: 41 -
Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?.
American journal of hematology.
2020
Article
GET IT
Times cited: 49 -
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2020
Academic Article
GET IT
Times cited: 9 -
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
Leukemia & lymphoma.
2018
Letter
GET IT
Times cited: 14 -
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017
Academic Article
GET IT
Times cited: 33 -
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Cancer chemotherapy and pharmacology.
2017
Academic Article
GET IT
Times cited: 1 -
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Leukemia & lymphoma.
2017
Article
GET IT
Times cited: 1 -
The high price of anticancer drugs: origins, implications, barriers, solutions.
Nature reviews. Clinical oncology.
2017
Information Resource
GET IT
Times cited: 134 -
Proteomic profiling in plasma cell disorders: a feasibility study.
Leukemia & lymphoma.
2016
Article
GET IT
Times cited: 7 -
Controversies in multiple myeloma: Evidence-based update.
Seminars in oncology.
2016
Information Resource
GET IT
Times cited: 4 -
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
Leukemia & lymphoma.
2016
Academic Article
GET IT
Times cited: 12 -
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
Clinical biochemistry.
2016
Academic Article
GET IT
Times cited: 56 -
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Best practice & research. Clinical haematology.
2016
Information Resource
GET IT
Times cited: 3 -
An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials.
JAMA oncology.
2016
Academic Article
GET IT
Times cited: 54 -
Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
JAMA.
2016
Article
GET IT
Times cited: 21 -
ASCO Plenary Sessions: impact, legacy, future.
Seminars in oncology.
2016
Information Resource
GET IT
Times cited: 1 -
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Mayo Clinic proceedings.
2016
Article
GET IT
Times cited: 12 -
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
Leukemia & lymphoma.
2016
Academic Article
GET IT
Times cited: 20 -
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
Blood.
2016
Article
GET IT
Times cited: 14 -
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 13 -
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
Haematologica.
2015
Article
GET IT
Times cited: 26 - Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. The oncologist. 2015 Academic Article GET IT
-
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
JAMA oncology.
2015
Academic Article
GET IT
Times cited: 257 -
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.
Blood.
2015
Article
GET IT
Times cited: 16 -
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
JAMA oncology.
2015
Academic Article
GET IT
Times cited: 61 -
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Nature reviews. Clinical oncology.
2015
Information Resource
GET IT
Times cited: 93 -
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.
Haematologica.
2014
Editorial Article
GET IT
Times cited: 3 -
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.
JAMA otolaryngology-- head & neck surgery.
2014
Conference Paper
GET IT
Times cited: 184 -
Dilemmas in treating smoldering multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Information Resource
GET IT
Times cited: 19 -
Comparative effectiveness questions in oncology.
The New England journal of medicine.
2014
Academic Article
GET IT
Times cited: 32 -
Minimal residual disease: what are the minimum requirements?.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Article
GET IT
Times cited: 16 -
Smoldering multiple myeloma: present position and potential promises.
European journal of haematology.
2013
Information Resource
GET IT
Times cited: 5 -
MGUS prevalence in a cohort of AML patients.
Blood.
2013
Article
GET IT
Times cited: 3 -
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood.
2012
Information Resource
GET IT
Times cited: 102 -
Myeloma and second primary cancers.
The New England journal of medicine.
2011
Article
GET IT
Times cited: 45 -
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
Blood.
2011
Academic Article
GET IT
Times cited: 169 -
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Leukemia & lymphoma.
2010
Information Resource
GET IT
Times cited: 26 -
Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation.
Transplantation.
2010
Academic Article
GET IT
Times cited: 19